HK1041263A1 - 3a, 4,5,9b-tetrahydro-1h-benz[e] indol-2-yl amine-derived neuropeptide y receptors ligands useful in the treatment of obesity and other disorders - Google Patents

3a, 4,5,9b-tetrahydro-1h-benz[e] indol-2-yl amine-derived neuropeptide y receptors ligands useful in the treatment of obesity and other disorders

Info

Publication number
HK1041263A1
HK1041263A1 HK02102941.4A HK02102941A HK1041263A1 HK 1041263 A1 HK1041263 A1 HK 1041263A1 HK 02102941 A HK02102941 A HK 02102941A HK 1041263 A1 HK1041263 A1 HK 1041263A1
Authority
HK
Hong Kong
Prior art keywords
benz
indol
obesity
tetrahydro
disorders
Prior art date
Application number
HK02102941.4A
Other languages
Chinese (zh)
Inventor
Dax Scott
Mcnally James
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Publication of HK1041263A1 publication Critical patent/HK1041263A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/60—Naphtho [b] pyrroles; Hydrogenated naphtho [b] pyrroles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK02102941.4A 1999-05-05 2002-04-18 3a, 4,5,9b-tetrahydro-1h-benz[e] indol-2-yl amine-derived neuropeptide y receptors ligands useful in the treatment of obesity and other disorders HK1041263A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13266099P 1999-05-05 1999-05-05
PCT/US2000/010981 WO2000068197A1 (en) 1999-05-05 2000-04-20 3a,4,5,9b-TETRAHYDRO-1H-BENZ[e]INDOL-2-YL AMINE-DERIVED NEUROPEPTIDE Y RECEPTORS LIGANDS USEFUL IN THE TREATMENT OF OBESITY AND OTHER DISORDERS

Publications (1)

Publication Number Publication Date
HK1041263A1 true HK1041263A1 (en) 2002-07-05

Family

ID=22455028

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02102941.4A HK1041263A1 (en) 1999-05-05 2002-04-18 3a, 4,5,9b-tetrahydro-1h-benz[e] indol-2-yl amine-derived neuropeptide y receptors ligands useful in the treatment of obesity and other disorders

Country Status (6)

Country Link
EP (1) EP1177172A1 (en)
AU (1) AU4659200A (en)
CA (1) CA2373035A1 (en)
HK (1) HK1041263A1 (en)
MX (1) MXPA01011321A (en)
WO (1) WO2000068197A1 (en)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7745216B2 (en) 1999-02-10 2010-06-29 Curis, Inc. Methods and reagents for treating glucose metabolic disorders
ES2353728T3 (en) 1999-02-10 2011-03-04 Curis, Inc. PEPTIDE YY (PYY) TO TREAT METABOLIC DISORDERS OF GLUCOSE.
US6989379B1 (en) 1999-04-22 2006-01-24 H. Lundbick A/S Selective NPY (Y5) antagonists
US6340683B1 (en) 1999-04-22 2002-01-22 Synaptic Pharmaceutical Corporation Selective NPY (Y5) antagonists (triazines)
EP1816127A1 (en) 1999-04-22 2007-08-08 H. Lundbeck A/S Triazine derivatives for use as selective npy (y5) antagonists
US7273880B2 (en) 1999-06-30 2007-09-25 H. Lunbeck A/S Selective NPY (Y5) antagonists
NZ540351A (en) 1999-11-26 2006-05-26 Shionogi & Co NPY Y5 antagonists
RU2275207C2 (en) * 2000-12-14 2006-04-27 Амилин Фармасьютикалз, Инк. Method for decreasing of nutrient availability and method for appetite suppression
AU2007200224B2 (en) * 2000-12-14 2009-10-01 Amylin Pharmaceuticals, Llc Peptide YY and peptide YY agonists for treatment of metabolic disorders
AU2002332054B2 (en) 2001-09-24 2007-11-08 Imperial Innovations Limited Modification of feeding behavior
CA2403307A1 (en) 2001-10-23 2003-04-23 Neurogen Corporation Substituted 2-cyclohexyl-4-phenyl-1h-imidazole derivatives
JP2005531571A (en) * 2002-05-23 2005-10-20 アボット・ラボラトリーズ Acetamides and benzamides useful for the treatment of sexual dysfunction
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
JP4806628B2 (en) 2003-05-05 2011-11-02 プロビオドルグ エージー Glutaminyl cyclase inhibitor
CN1902177A (en) 2003-09-22 2007-01-24 万有制药株式会社 Novel piperidine derivative
EP2338490A3 (en) 2003-11-03 2012-06-06 Probiodrug AG Combinations useful for the treatment of neuronal disorders
BRPI0507485A (en) 2004-02-05 2007-07-10 Probiodrug Ag new glutaminyl cyclase inhibitors
EP1789440A4 (en) 2004-02-11 2008-03-12 Amylin Pharmaceuticals Inc Pancreatic polypeptide family motifs and polypeptides comprising the same
EP1734963A4 (en) 2004-04-02 2008-06-18 Merck & Co Inc Method of treating men with metabolic and anthropometric disorders
ATE427759T1 (en) 2004-11-01 2009-04-15 Amylin Pharmaceuticals Inc TREATMENT OF OBESITY AND RELATED DISEASES
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
RU2417985C2 (en) 2005-05-30 2011-05-10 Баниу Фармасьютикал Ко., Лтд. Novel piperidine derivatives
CA2618112A1 (en) 2005-08-10 2007-02-15 Banyu Pharmaceutical Co., Ltd. Pyridone compound
BRPI0614649A2 (en) 2005-08-11 2011-04-12 Amylin Pharmaceuticals Inc hybrid polypeptides with selectable properties
EP2330124B1 (en) 2005-08-11 2015-02-25 Amylin Pharmaceuticals, LLC Hybrid polypeptides with selectable properties
AU2006282260A1 (en) 2005-08-24 2007-03-01 Msd K.K. Phenylpyridone derivative
EP1939194A4 (en) 2005-09-07 2010-12-08 Banyu Pharma Co Ltd Bicyclic aromatic substituted pyridone derivative
BRPI0616463A2 (en) 2005-09-29 2011-06-21 Merck & Co Inc compound, pharmaceutical composition, and use of a compound
WO2007048027A2 (en) 2005-10-21 2007-04-26 Novartis Ag Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent
AU2006307046A1 (en) 2005-10-27 2007-05-03 Msd K.K. Novel benzoxathiin derivative
NZ568292A (en) 2005-11-10 2011-08-26 Msd Kk Spiro[cyclohexane-1,1'-(3'H)-4'-azaisobenzofuran]-4-carboxamide derivatives
BRPI0710950A2 (en) 2006-04-28 2012-06-26 Shionogi & Co amine derivative having npi 53 y5 receptor antagonistic activity a61p 3/04 a61p 9/04 a61p 9/12 a61p 15/00 a61p 25/08 a61p 25/20 a61p 25/24 a61p 43/00 c07c 311/07 c07c 317 / 36 c07d 207/325 c07d 211/14 c07d 213/38 c07d 213/74 c07d 213/82 c07d 215/38 c07d 217/04 c07d 217/14 c07d 217/22 c07d 219/10 c07d 231/38 c07d 233/61 c07d 235/30 c07d 237/20 c07d 237/22 c07d 237/34 c07d 239/42 c07d 241/20 c07d 261/14 c07d 261/20 c07d 263/58 c07d 265/30 c07d 265/36 c07d 267/14 c07d 275 / 02 c07d 277/28 c07d 277/62 c07d 277/82 c07d 295/12 c07d 295/18 c07d 333/36 c07d 333/40 c07d 333/66 c07d 333/72 c07d 403/04 c07d 409/04 c07d 413/04 c07d 417/12 c07d 498/04 c07d 513/04
CA2664113C (en) 2006-09-22 2013-05-28 Merck & Co., Inc. Use of platencin and platensimycin as fatty acid synthesis inhibitors to treat obesity, diabetes and cancer
JPWO2008038692A1 (en) 2006-09-28 2010-01-28 萬有製薬株式会社 Diaryl ketimine derivatives
WO2008055945A1 (en) 2006-11-09 2008-05-15 Probiodrug Ag 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
ATE554085T1 (en) 2006-11-30 2012-05-15 Probiodrug Ag NEW INHIBITORS OF GLUTAMINYL CYCLASE
TWI428346B (en) 2006-12-13 2014-03-01 Imp Innovations Ltd Novel compounds and their effects on feeding behaviour
EP2117540A1 (en) 2007-03-01 2009-11-18 Probiodrug AG New use of glutaminyl cyclase inhibitors
CA2682727C (en) 2007-04-02 2016-03-22 Banyu Pharmaceutical Co., Ltd. Indoledione derivative
JP5667440B2 (en) 2007-04-18 2015-02-12 プロビオドルグ エージー Thiourea derivatives as glutaminyl cyclase inhibitors
MX354786B (en) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS, INFLAMMATION, CANCER and OTHER DISORDERS.
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
SA08290668B1 (en) 2007-10-25 2012-02-12 شيونوجي آند كو.، ليمتد Amine Derivatives having NPY Y5 receptor antagonistic activity and the uses thereof
CA2714617A1 (en) 2008-03-06 2009-09-11 Banyu Pharmaceutical Co., Ltd. Alkylaminopyridine derivative
US20110015198A1 (en) 2008-03-28 2011-01-20 Banyu Pharmaceutical Co., Inc. Diarylmethylamide derivative having melanin-concentrating hormone receptor antagonism
CA2726917C (en) 2008-06-04 2018-06-26 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP2301936A1 (en) 2008-06-19 2011-03-30 Banyu Pharmaceutical Co., Ltd. Spirodiamine-diarylketoxime derivative
WO2010009319A2 (en) 2008-07-16 2010-01-21 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
EP2319841A1 (en) 2008-07-30 2011-05-11 Msd K.K. (5-membered)-(5-membered) or (5-membered)-(6-membered) fused ring cycloalkylamine derivative
CA2741125A1 (en) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
EP2350010B1 (en) 2008-10-30 2014-03-26 Merck Sharp & Dohme Corp. Isonicotinamide orexin receptor antagonists
CN102271509A (en) 2008-10-31 2011-12-07 默沙东公司 Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US20110243940A1 (en) 2008-12-16 2011-10-06 Schering Corporation Bicyclic pyranone derivatives and methods of use thereof
US20110245209A1 (en) 2008-12-16 2011-10-06 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
US8227618B2 (en) 2009-04-23 2012-07-24 Shionogi & Co., Ltd. Amine-derivatives having NPY Y5 receptor antagonistic activity and the uses thereof
SG178953A1 (en) 2009-09-11 2012-04-27 Probiodrug Ag Heterocylcic derivatives as inhibitors of glutaminyl cyclase
US8895596B2 (en) 2010-02-25 2014-11-25 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
US9181233B2 (en) 2010-03-03 2015-11-10 Probiodrug Ag Inhibitors of glutaminyl cyclase
AU2011226074B2 (en) 2010-03-10 2015-01-22 Vivoryon Therapeutics N.V. Heterocyclic inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5)
US8541596B2 (en) 2010-04-21 2013-09-24 Probiodrug Ag Inhibitors
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
EP2677869B1 (en) 2011-02-25 2017-11-08 Merck Sharp & Dohme Corp. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
ES2570167T3 (en) 2011-03-16 2016-05-17 Probiodrug Ag Benzimidazole derivatives as glutaminyl cyclase inhibitors
AR088352A1 (en) 2011-10-19 2014-05-28 Merck Sharp & Dohme ANTAGONISTS OF THE RECEIVER OF 2-PIRIDILOXI-4-NITRILE OREXINE
CA2880901A1 (en) 2012-08-02 2014-02-06 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
WO2014130608A1 (en) 2013-02-22 2014-08-28 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
EP2970119B1 (en) 2013-03-14 2021-11-03 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
JP6606491B2 (en) 2013-06-05 2019-11-13 シナジー ファーマシューティカルズ インコーポレイテッド Ultra high purity agonist of guanylate cyclase C, method for producing and using the same
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
DK3186242T3 (en) 2014-08-29 2021-12-20 Tes Pharma S R L ALFA-AMINO-BETA-CARBOXYMUCONSIDE-SEMIALDEHYDE-DECARBOXYLASE INHIBITORS
AR109950A1 (en) 2016-10-14 2019-02-06 Tes Pharma S R L A-AMINO-b-CARBOXIMUCONIC SEMIAL DEHYDE DECARBOXYLASE ACID INHIBITORS
EP3551176A4 (en) 2016-12-06 2020-06-24 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
ES2812698T3 (en) 2017-09-29 2021-03-18 Probiodrug Ag Glutaminyl cyclase inhibitors
KR20210111248A (en) 2018-11-20 2021-09-10 테스 파마 에스.알.엘. Inhibitors of α-amino-β-carboxymuconic acid semialdehyde decarboxylase
US11098029B2 (en) 2019-02-13 2021-08-24 Merck Sharp & Dohme Corp. 5-alkyl pyrrolidine orexin receptor agonists
EP4010314B1 (en) 2019-08-08 2024-02-28 Merck Sharp & Dohme LLC Heteroaryl pyrrolidine and piperidine orexin receptor agonists
TW202227417A (en) 2020-08-18 2022-07-16 美商默沙東藥廠 Bicycloheptane pyrrolidine orexin receptor agonists

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997020823A2 (en) * 1995-12-01 1997-06-12 Novartis Ag 2-amino quinazoline derivatives as npy receptor antagonists
WO1997019682A1 (en) * 1995-12-01 1997-06-05 Synaptic Pharmaceutical Corporation Aryl sulfonamide and sulfamide derivatives and uses thereof
JP2000510164A (en) * 1997-02-14 2000-08-08 バイエル・コーポレーシヨン Amide derivatives as selective neuropeptide Y receptor antagonists
ATE269846T1 (en) * 1998-04-29 2004-07-15 Ortho Mcneil Pharm Inc N-SUBSTITUTED AMINOTETRALINES AS NEUROPEPTIDE Y Y5 RECEPTOR LIGANDS AND THEIR USE IN THE TREATMENT OF OBESITY AND OTHER DISEASES
DE69922676T2 (en) * 1998-10-07 2005-12-15 Ortho-Mcneil Pharmaceutical, Inc. N-ARALKYLAMINOTETRALINES AS NEUROPEPTIDE Y-Y5 RECEPTOR LIGANDS

Also Published As

Publication number Publication date
CA2373035A1 (en) 2000-11-16
EP1177172A1 (en) 2002-02-06
AU4659200A (en) 2000-11-21
WO2000068197A1 (en) 2000-11-16
MXPA01011321A (en) 2003-08-01

Similar Documents

Publication Publication Date Title
HK1041263A1 (en) 3a, 4,5,9b-tetrahydro-1h-benz[e] indol-2-yl amine-derived neuropeptide y receptors ligands useful in the treatment of obesity and other disorders
MXPA02000927A (en) Amine and amide derivatives as ligands for the neuropeptide y y5 receptor useful in the treatment of obesity and other disorders.
IL147582A0 (en) 2-arylimino-2, 3-dihydrothiazoles, and their use thereof as somatostatin receptor ligands
HUP0104816A3 (en) 3-azabicyclo[3.1.0] hexane derivatives as opiate receptors ligands and process for their preparation
HUP0402113A3 (en) 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity, preparation and use thereof
AU2003291609A1 (en) Cb 1/cb 2 receptor ligands and their use in the treatment of pain
HUP0100069A3 (en) 4(3)substituted-4(3)-aminomethyl-pyran, or -thiopyran-piperidine derivatives, their preparation and their use in the treatment of neurological disorders
HK1070361A1 (en) 5-sulphanyl-4h-1,2,4-triazole derivatives and their use to treat disorders associated with somatostatine
IL148419A0 (en) Benzodiazepine derivatives, the production and use thereof
GB0125934D0 (en) Alzheimer's disease secretase,app substrates therefor,and uses therefor
HK1056877A1 (en) Mch antagonists and their use in the treatment of obesity.
AU9112201A (en) Pulmonary delivery in treating disorders of the central nervous system
GB0109414D0 (en) Well treatment fluids and methods for the use thereof
EP1233785A4 (en) "bonzo" chemokine receptor antibodies and ligands
HK1052932A1 (en) 1,5-Disubstituted-3,4-dihydro-1h-pyrimido Ä4,5-dÜpyrimidin-2-one compounds and their use in treatingcsbp/p38 kinase mediated diseases
HUP0203529A3 (en) Treating sleep disorders using desloratadine
IL150022A0 (en) Imidazo [1,3,5] triazinones and the use thereof
IL156340A0 (en) 3-indoline derivatives useful in the treatment of psychiatric and neurologic disorders
HK1041226A1 (en) Methods and compositions for treating gastro-esophageal reflux disease
GB2370233B (en) Apparatus for use in behaviour modification and the like
AU8177801A (en) 1,4-diazepan-2,5-dione derivatives and their use as nk-1 receptor antagonists
AU3958902A (en) Crf receptor antagonists and methods relating thereto
GB2364303B (en) Semiconducting ceramic material and electronic part employing the same
GB9820014D0 (en) Receptor antagonists and uses thereof
HUP0201508A3 (en) Granular water-dispersible agents and process for producing the same